Xgenera is dedicated to transforming cancer diagnosis through their groundbreaking multi-cancer early detection (MCED) test. With a mission to save lives by identifying cancer at its earliest stages, Xgenera leverages cutting-edge technology and advanced algorithms to detect a wide range of cancers with exceptional accuracy.
By detecting cancer earlier, when treatment options are most effective, Xgenera aims to improve patient outcomes and ultimately reduce the global burden of cancer.
Backed by data from large patient cohorts and ongoing research, Xgenera's MCED test holds the potential to revolutionise cancer diagnosis around the world. With a commitment to empowering individuals and healthcare providers with timely, actionable information, Xgenera is at the forefront of the fight against cancer, paving the way for a future where early detection saves lives.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Southampton, Hampshire, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.xgenera.com/
- Keywords
- Empirical Ventures.
- HQ
- Southampton, Hampshire
Xgenera Questions
Xgenera's website is https://www.xgenera.com/
Xgenera's LinkedIn profile is https://uk.linkedin.com/company/xgenera
Xgenera has
8 employees.
View email and phone details for 8
employees at Xgenera.
Xgenera's industry is
Biotechnology Research
Xgenera's top competitors are
Nihr (National Institute For Health And Care Research),
Empirical Ventures,
Proteotype Diagnostics,
Pbd Biotech,
Youseq,
Silveray,
Autolus Therapeutics,
Intodna,
Ifast Diagnostics,
Future Worlds.
Xgenera's categories are Biotechnology Research
Xgenera's founding year is 2023
